The approval of the anti-CD38 antibody daratumumab has provided a valuable new option for patients with light-chain amyloidosis. Review this expert commentary to get a top-level view of this disease and current best practices.
Download this short summary slideset covering key recent advances in the treatment of systemic amyloidosis.
In this module, Shaji K. Kumar, MD, provides expert insights on the diagnoses of AL and ATTR amyloidosis and selecting optimal therapies. Beth Faiman, PhD, MSN, APRN-BC, AOCN, also provides expert insights on supportive care for patients with AL and ATTR amyloidosis.
Downloadable slideset on diagnosing and managing AL and ATTR amyloidosis.